<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Kim C</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Bruton's tyrosine kinase (BTK) and interleukin (IL)-2 Inducible T-cell Kinase (ITK) inhibitors have anti-inflammatory properties. We investigated the therapeutic effect of ibrutinib, an orally bioavailable BTK/ITK inhibitor, in a mouse model of Graves' orbitopathy (GO).&lt;h4>Methods&lt;/h4>Genetic immunization was performed through intramuscular administration of the recombinant plasmid, pCMV6-hTSHR cDNA, to 8-week-old female BALB/c mice. Serum levels of T3, T4, and thyroid-stimulating hormone receptor (TSHR) antibodies (TRAbs) were quantified using enzyme-linked immunosorbent assay. Histopathological changes in orbital tissues were examined using immunohistochemistry (IHC) staining for TSHR and various inflammatory markers. Following successful genetic immunization, ibruti</pubmed_abstract><journal>Frontiers in endocrinology</journal><pagination>1420024</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11392736</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.</pubmed_title><pmcid>PMC11392736</pmcid><pubmed_authors>Kim C</pubmed_authors><pubmed_authors>Yang JW</pubmed_authors><pubmed_authors>Chung JK</pubmed_authors><pubmed_authors>Park JH</pubmed_authors><pubmed_authors>Jang SY</pubmed_authors><pubmed_authors>Choi YJ</pubmed_authors><pubmed_authors>Yoon JS</pubmed_authors><pubmed_authors>Jun HO</pubmed_authors><pubmed_authors>Park TK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.</name><description>&lt;h4>Introduction&lt;/h4>Bruton's tyrosine kinase (BTK) and interleukin (IL)-2 Inducible T-cell Kinase (ITK) inhibitors have anti-inflammatory properties. We investigated the therapeutic effect of ibrutinib, an orally bioavailable BTK/ITK inhibitor, in a mouse model of Graves' orbitopathy (GO).&lt;h4>Methods&lt;/h4>Genetic immunization was performed through intramuscular administration of the recombinant plasmid, pCMV6-hTSHR cDNA, to 8-week-old female BALB/c mice. Serum levels of T3, T4, and thyroid-stimulating hormone receptor (TSHR) antibodies (TRAbs) were quantified using enzyme-linked immunosorbent assay. Histopathological changes in orbital tissues were examined using immunohistochemistry (IHC) staining for TSHR and various inflammatory markers. Following successful genetic immunization, ibruti</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-04T03:08:02.581Z</modification><creation>2025-04-04T09:48:48.51Z</creation></dates><accession>S-EPMC11392736</accession><cross_references><pubmed>39280007</pubmed><doi>10.3389/fendo.2024.1420024</doi></cross_references></HashMap>